Basking Biosciences

Focus: Basking Biosciences is a public biotechnology company focused on reversible thrombolytic therapy for acute ischemic stroke, operating in the high-unmet-need neurology and cardiovascular space. The company is early-stage with a focused pipeline and no approved commercial products.

Neurology Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Basking Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Basking Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BB-025

Pharmacodynamics

Phase 1

DTRI-031

Pharmacokinetics

Phase 1

Clinical Trials (1)

Help build intelligence for Basking Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-impact neurology indication (acute ischemic stroke) with significant unmet medical need and large addressable market
Public company status provides potential equity upside and access to capital markets for development funding
Early-stage pipeline allows meaningful individual contribution to drug development from Phase 1/2 stage onward

Watch Out For

No marketed products and zero active job postings signal minimal hiring and possible resource constraints or early-stage scaling challenges
Early pipeline stage (Phase 2 lead program) with no Phase 3 initiations on horizon means 3-5+ years before potential value inflection or regulatory catalysts
Missing financial data (revenue, cash position, R&D spend) prevents assessment of company stability and runway

Generated by Claude from Basking Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05005520Study of DTRI-031 in Healthy Volunteers

Phase 1

BB-031

Acute Ischemic Stroke

Phase 2

Clinical Trials (2)

NCT06226805Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

Phase 2

NCT07202663Study of BB-025, Alone and After BB-031, in Healthy Volunteers

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline